Effects of metrontoazole and its metabolites on histamine immunosuppression activity

Life Sciences

Volumn 59, Issue 4, 1996, Pages 285-297

  Elizondo, Guillermo ^a   Ostrosky Wegman, Patricia ^a,b  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Cimetidine; Histamine; Imidazole; Lymphocyte proliferation; Metronidazole

Indexed keywords

ACETIC ACID DERIVATIVE; CIMETIDINE; DRUG METABOLITE; HISTAMINE; METRONIDAZOLE;

ARTICLE; COMPETITIVE INHIBITION; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG EFFECT; HELPER CELL; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; PERIPHERAL LYMPHOCYTE; TARGET CELL;

ADULT; ANALYSIS OF VARIANCE; CELL DIVISION; CELLS, CULTURED; CIMETIDINE; HISTAMINE; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; METRONIDAZOLE; MITOSIS; MOLECULAR STRUCTURE; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0030016654     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/0024-3205(96)00297-4     Document Type: Article

References (20)

1. M.E. OSBAND, Y.J. SHEN, M. SHLESINGER, A. BROWN, D. HAMILTON, E. COHEN, P. LAVIN and R. McCAFFREY, Lancet, 21 636-638 (1981).
2. J.L. FOSTER, P.J CONREY, A.J. SEARLE and R.L. WILLSON, Br. J. Cancer, 33 485-490 (1976).
3. J. AVELLA, H.J. BINDER, J.E. MADSEN and P.W. ASKENASE, Lancet, 25 624-326 (1978).
4. C.G. MOERTEL, T.R. FLEMING and J.S. MAcDONAL, New Engl. J. Med., 322 352-358 (1990).
5. J. SYMOENS and M. ROSENTHAL, J.Reticul.Soc., 21 121-175 (1977).
6. V.J. MERLUZZI, A.M. BADGER, C.W. KAISER and S.R. COOPERBAND, Clin. Exp. Immunol., 22 486-492 (1975).
7. P.O. OGUNBIBYI, W.D. BLACK and P. EYRE, J.Vet.Pharmacol.Ther., 11 338-344 (1988).
8. S.J. POWELL, Advan. Pharmacol. Chemother, 10 91-103 (1966).
9. P. COSAR and L. JULOUE, Ann. Institut Pasteur, 96 238-241 (1959).
10. R.B. KHAMBATTA, Ann. Trop. Med. Parasitol., 65 487-489 (1971).
11. I. LARES, J.CRAVIOTO, P. SANTIAGO AND B. PEREZ, Scand. J. Infect. Dis., 25 115-121.
12. G. ELIZONDO, R. MONTERO, J.E. HERRERA, E. HONG and P. OSTROSKY-WEGMAN, Mutation Res., 305 133-138 (1994).
13. S. LOFT and H.E. PULSEN, Biochem. Pharmacol., 38 1125-1136 (1988).
14. S. LOFT, S.V. OTTON,M.S. LENNARD, G.T. TUCKER and H.E. POULSEN, Biochem. Pharmacol., 41 1127-1134 (1991).
15. J.E. STAMBAUGH, L.G. FEO and R.W. MANTHEI J.Pharm. Exp. Ther., 161 373-381 (1968).
16. V.BARH and U.ULLMAN, Eur. J.Clin.Microbiol., 2 568-570 (1983).
17. K.L. MELMON and M.M. KHAN, Trens. Pharmacol. Scie., 8 437-441 (1987).
18. R.E. ROCKLIN, J.Clin.Invest., 57 1051-1058 (1976).
19. D.J. BEER and R.E. ROCKLIN, CRC Crit.Rev.Immunol., 7 55-91(1987).
20. R. CARLSSON, M. DOHLSTEN and H.O. SJOGREN, Cell Immunol., 96 104-112 (1985).